FDA Call for Comments: Draft Blueprint for Opioid Prescribing

The Food and Drug Administration (FDA) today released a draft "blueprint" to guide the development of prescriber training modules for the use of long-acting and extended-release opioid drugs. The FDA is inviting stakeholder comment on the draft document, which will be incorporated into the final blueprint posted to the FDA site for mongoing use by continuing education (CE) providers in developing courses for the safe prescribing of opioids. Developed by FDA with the input of other federal agencies, the blueprint “is a basic outline and the core messages that FDA believes should be conveyed to prescribers in a basic 2 to 3hour educational module. Docket No. FDA-2011-D-0771. Comments are due by December 7, 2011.